Bulgarian pharmaceutical market, reimbursement, pricing and consumption information.
 
The Bulgarian pharmaceutical market has been steadily growing over the past few years, with $ per capita growing at a CAGR of 3.1% since 2018, reaching roughly 1.4 billion USD in 2021. Governmental expenditure in the health sector has also been increasing, and in 2022 the national healthcare budget had set itself a new record at 4 billion USD, in addition to the budget for drugs, also reaching a record at 1.2 billion USD. In the year 2021, Bulgaria spent 8.1% of its GDP on healthcare, and by doing so passed the EU threshold of 8%. The growth is mainly attributed to the development of the hospital sector, which grew by 25%, reaching roughly 500 million USD. The pharmacy market segment also grew by 5.8% amounting to 2 billion USD in revenue. The governmental body responsible for examining drugs and medical devices to be launched in Bulgaria is the BDA (Bulgarian drug agency), which has received from the FDA confirmation of manufacturing and inspection at a level equivalent to the U.S. standard.
The public procurement sector amounts to 15% of total GDP in Bulgaria, with the two main fields being construction and health. Roughly 20% of Bulgarian procurement contracts in 2022 are health related, of which over 50% are contracts for the procurement of pharmaceuticals.

Pharma14 tracks the Bulgarian market with monthly updates including MA holder, manufacturer data, reimbursed consumption and pricing data.
Sample Data:
2019-2021. Adalimumab - Humira, pre-filled syringe 40 mcg/04. ml, X2 consumption data (reimbursed).

Sample Data:
Current Adalimumab pricing data (November 2022)